There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ritter Pharmaceuticals (NASDAQ:RTTR), Dicerna Pharma (NASDAQ:DRNA) and Sophiris Bio (NASDAQ:SPHS) with bullish sentiments.
Ritter Pharmaceuticals (RTTR)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ritter Pharmaceuticals, with a price target of $15. The company’s shares closed yesterday at $2.01, close to its 52-week low of $1.83.
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.9% and a 36.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Ritter Pharmaceuticals is a Moderate Buy with an average price target of $15.
See today’s analyst top recommended stocks >>
Dicerna Pharma (DRNA)
Dicerna Pharma received a Buy rating and a $21 price target from H.C. Wainwright analyst Ed Arce today. The company’s shares closed yesterday at $14.82, close to its 52-week high of $15.80.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 19.2% and a 40.8% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Aurinia Pharmaceuticals.
Dicerna Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $17.25, implying a 16.4% upside from current levels. In a report issued on August 8, Stifel Nicolaus also reiterated a Buy rating on the stock with a $20 price target.
.
Sophiris Bio (SPHS)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Sophiris Bio today and set a price target of $4.30. The company’s shares closed yesterday at $2.74.
Pantginis said:
“Valuation and risks to price target achievement. We maintain our Buy rating and $4.30. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, topsalysin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -11.2% and a 33.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sophiris Bio with a $6.43 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
